【LYC 0075 交流专区】(前名 MEXTER)

icy97

LYC HEALTHCARE BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Placement Shares issued pursuant to the Proposed Private Placement
No. of shares issued under this corporate proposal	4,000,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.3200
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	336,864,340
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 62,895,404.480
Listing Date	20 Nov 2019

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2019	30 Sep 2018	30 Sep 2019	30 Sep 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,053	5,662	5,739	10,406
2	Profit/(loss) before tax	-2,053	-1,465	-3,645	-3,051
3	Profit/(loss) for the period	-2,051	-1,463	-3,641	-3,047
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,994	-1,588	-3,537	-3,072
5	Basic earnings/(loss) per share (Subunit)	-0.61	-0.49	-1.09	-1.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0700		0.0700

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR THE "COMPANY") - INCORPORATION OF A WHOLLY OWNED SUB-SUBSIDIARY
1. Introduction The Board of Directors of LYC wishes to announce that LYC Mother & Child Centre Sdn Bhd (Registration No. 201101044567 (972687-K)) (“LYCMC”), a wholly owned subsidiary of the Company, has on 6 December 2019 incorporated a wholly owned subsidiary known as LYC Child Care Centre Sdn Bhd (Registration No. 201901044276 (1353606-P)) ("LYCCCC"). 2. Information of LYCCCC LYCCCC was incorporated on 6 December 2019 as a private limited company by shares in Malaysia under the Companies Act, 2016. The share capital of LYCCCC as at the date of announcement is Ringgit Malaysia One Hundred Only (RM100.00) comprising One Hundred (100) ordinary shares. LYCMC holds One Hundred (100) ordinary shares for Ringgit Malaysia One Hundred only (RM100.00), representing 100% shareholding of LYCCCC. The intended principal activities of LYCCCC are to carry on the business of child daycare activities. The current directors of LYCCCC are Mr Sui Diong Hoe and Encik Ahmad Rafique bin Mat Tahir. 3. Rationale Through the Company’s operations of confinement services in Taman Tun Dr Ismail and Puchong centres, LYC has observed strong demand from its customers for child care services beyond the confinement period of one (1) month. Parents are increasingly growing concerned about the quality child care providers available in the market currently and are more willing to pay for premium prices for reputable service providers. The Company believe that as it have a captive market via the confinement services, more parents are willing to consider the Company’s child care services for children aged two (2) months to two (2) years old. These customers will be more assured of the high quality and standard of care by LYC and will allow the Company to further maximize the lifetime value of its customers. As part of the first phase, LYCCCC will seek to offer the child care services in both the Taman Tun Dr Ismail and Puchong premises for children aged 2 months to 2 years old. Additionally LYCCCC customers could be potential customers of LYC Family Clinic services, which may generate synergies. 4. Financial Effect of the Incorporation of LYCCCC The incorporation of LYCCCC does not have any effect on the share capital and substantial shareholders’ shareholdings of LYC. It is also not expected to have any material effect on the net assets, gearing and earnings of LYCCCC for the financial year ending 31 March 2020. 5. Directors’ and Major Shareholders’ Interests Mr Sui Diong Hoe is the Managing Director cum Group Chief Executive Officer and Encik Ahmad Rafique bin Mat Tahir is the Group Chief Operating Officer of LYC. Save as disclosed above, none of the Directors and/or major shareholders of LYC or persons connected with them, have any direct or indirect interest in the incorporation of LYCCCC. This announcement is dated 10 December 2019.

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR THE "COMPANY") - INCORPORATION OF A 50% OWNED COMPANY
1. Introduction The Board of Directors of LYC wishes to announce that the Company has on 20 December 2019 incorporated a Fifty percent (50%) owned company known as LYC & Chung Fertility Centre Sdn Bhd (Registration No. 201901045953 (1355283-K)) ("LYCCF"). The remaining Fifty percent (50%) shareholding is held by Dr Chung Chow Cheang (NRIC No. 591104-08-6329)(“Dr Chung”). 2. Information of LYCCF LYCCF was incorporated on 20 December 2019 as a private limited company by shares in Malaysia under the Companies Act, 2016. The share capital of LYCCF as at the date of announcement is Ringgit Malaysia One Hundred Only (RM100.00) comprising One Hundred (100) ordinary shares. LYC holds Fifty (50) shares for Ringgit Malaysia Fifty only (RM50.00), representing Fifty percent (50%) shareholding of LYCCF while Dr Chung holds Fifty (50) shares for Ringgit Malaysia Fifty only (RM50.00), representing Fifty percent (50%) shareholding of LYCCF. The intended principal activities of LYCCF are to carry on the business of providing Assisted Reproductive Technology (“ART”) services, In Vitro Fertilisation (“IVF”), specialist consultancy services, obstetrics and gynecological services, and providing relevant laboratory services in connection with investigative procedures and other medical and pharmaceutical services. The current directors of LYCCF are Mr Sui Diong Hoe and Dr Chung Chow Cheang. 3. Information of Dr. Chung Chow Cheang Dr Chung is a highly qualified fertility specialist with qualifications from Bachelor of Medicine & Bachelor of Surgery (MBBS)(Malaysia), Member / Fellow of the Royal College of Obstetricians and Gynaecologists (MRCOG and FRCOG UK) and more than 25 years’ experience in the industry. Dr Chung’s area of specialty includes General Obstetrics & Gynaecology, Gynaecological Disorder & Cancer Screening, Pelvic Floor Disorder, Sexually Transmitted Diseases(STDs), Infertility Comprehensive Diagnostic, Infertility / Assisted Reproductive Technologies, Counseling and Treatment. Dr Chung was previously a Head of Lembaga Penduduk dan Pembangunan Keluarga Negara (LPPKN) Fertility Unit which is under Kementrian Pembangunan Wanita, Keluarga Dan Masyarakat. Dr Chung currently operates his own fertility clinic called CC Chung Gynaecology & Assisted Reproduction in Jalan Binjai, PNB Perdana, 50450 Kuala Lumpur. 4. Rationale The Company will look to leverage on Dr. Chung’s extensive track record in the fertility industry and LYC’s healthcare and marketing expertise to drive the business of LYCCF. The move is also in line with the Company’s plans to further diversify its business in the healthcare space, with a focus on medical tourism. After China scrapped its one-child policy in October 2015, Malaysian Healthcare Travel Council (“MHTC”) estimates there are around 90 million couples in China looking to conceive a second child. Out of these, 40 million are over 40 years of age, it added. MHTC noted that fertility and cardiology treatments are among the top five treatments sought after by healthcare travellers to Malaysia, alongside orthopaedics, oncology and aesthetics. Malaysia IVF rates are comparatively cheaper than the other medical tourism countries such as Singapore. This is a potential selling factor which can be tapped on to attract customers. Based on Malaysia’s Budget 2020, Malaysian couples looking to try IVF may withdraw from their Employees Provident Fund (“EPF”) to fund the procedure. Income tax relief of up to RM6,000 given on expenses incurred for medical treatment of serious illnesses will be expanded to include expenses incurred on fertility treatment. Additionally LYCCF customers could be potential customers of LYC Mother & Child Centre’s confinement services, which may generate synergies. 5. Financial Effect of the Incorporation of LYCCF The incorporation of LYCCF does not have any effect on the share capital and substantial shareholders’ shareholdings of LYC. It is also not expected to have any material effect on the net assets, gearing and earnings of LYC for the financial year ending 31 March 2020. 6. Directors’ and Major Shareholders’ Interests Mr Sui Diong Hoe is the Managing Director cum Group Chief Executive Officer of LYC. Save as disclosed above, none of the Directors and/or major shareholders of LYC or persons connected with them, have any direct or indirect interest in the incorporation of LYCCF. This announcement is dated 20 December 2019.

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR THE "COMPANY") - INCORPORATION OF A 51% OWNED SUBSIDIARY
1. Introduction The Board of Directors of LYC wishes to announce that the Company has on 27 December 2019 incorporated a Fifty-One percent (51%) owned subsidiary known as LYC Osteoporosis & Chronic Disease Sdn Bhd (Registration No. 201901046531 (1355861-H)) ("LYCOCD"). The remaining Forty-Nine percent (49%) shareholding is held by Dr. Ting Choon Meng (Republic of Singapore Identity Card No. S1345465E)(“Dr. Ting”). 2. Information of LYCOCD LYCOCD was incorporated on 27 December 2019 as a private limited company by shares in Malaysia under the Companies Act, 2016. The share capital of LYCOCD as at the date of announcement is Ringgit Malaysia One Hundred Only (RM100.00) comprising One Hundred (100) ordinary shares. LYC holds Fifty-One (51) shares for Ringgit Malaysia Fifty One only (RM51.00), representing Fifty-One percent (51%) shareholding of LYCOCD while Dr. Ting holds Forty-Nine (49) shares for Ringgit Malaysia Forty-Nine only (RM49.00), representing Forty-Nine percent (49%) shareholding of LYCOCD. The intended principal activities of LYCOCD are to carry on the business of providing osteoporosis medical services, chronic medical services, specialist consultancy services and other medical and pharmaceutical services. The current directors of LYCOCD are Mr Sui Diong Hoe, Dr. Ting Choon Meng and Dr. Tan Su-Lin. 3. Information of Dr. Ting Choon Meng Dr. Ting specializes in treatment of patients primarily for chronic illnesses for over 30 years. Dr. Ting is a medical doctor, serial inventor of medical devices and an author. He is in private practice in Singapore for more than 20 years. He is also the inventor of the BPro which is the first wrist-worn device capable of capturing 24 hour blood pressure readings and pulse waveform analysis both at the same time. This patented invention which is Food and Drug Administration (FDA) approved has won awards from World Economic Forum and Frost & Sullivan as Monitoring Technology of the year 2007. BPro is now commercialized in more than 25 countries in the world. Dr. Ting holds an impressive record in medicine for having treated the most osteo-arthritic - or worn out - knees with viscosupplementation ("VSP") in the world. He has treated over 25,000 knees since he discovered VSP in 1991. Dr. Ting currently owns and operates T&T Family Health Clinic & Surgery located at 181 Kitchener Road #01-36/38, Parkroyal Hotel Shopping Arcade. 4. Rationale The Company will look to leverage on Dr. Ting’s extensive track record in the osteoporosis and chronic disease industry and LYC’s healthcare and marketing expertise to drive the business of LYCOCD. The move is also in line with the Company’s plans to further diversify its business in the healthcare space, with a focus on medical tourism. According to World Health Organization, in Malaysia, chronic diseases accounted for 71% of all deaths in 2002, which represents 85,000 out of 119,000 deaths in that year. A Health and Morbidity Survey in 2015 found that 47.7% of Malaysians had high cholesterol levels while 17.7% were deemed obese. Non-communicable chronic diseases such as diabetes, hypertension and hyperlipidemia (high cholesterol levels) among Malaysians above 18 is very high. With an increasingly ageing population and improving income levels, more people are exposed chronic diseases and will seek the kind of services to be provided by LYCOCD. 5. Financial Effect of the Incorporation of LYCOCD The incorporation of LYCOCD does not have any effect on the share capital and substantial shareholders’ shareholdings of LYC. It is also not expected to have any material effect on the net assets, gearing and earnings of LYC for the financial year ending 31 March 2020. 6. Directors’ and Major Shareholders’ Interests Mr Sui Diong Hoe is the Managing Director cum Group Chief Executive Officer of LYC. Save as disclosed above, none of the Directors and/or major shareholders of LYC or persons connected with them, have any direct or indirect interest in the incorporation of LYCOCD. This announcement is dated 27 December 2019.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2019	31 Dec 2018	31 Dec 2019	31 Dec 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,597	1,807	9,336	5,133
2	Profit/(loss) before tax	-2,207	-2,200	-5,852	-5,287
3	Profit/(loss) for the period	-2,204	-514	-5,845	-3,597
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,056	-520	-5,593	-3,628
5	Basic earnings/(loss) per share (Subunit)	-0.61	-0.16	-1.70	-1.22
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0600		0.0700

icy97

LYC HEALTHCARE BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Placement Shares issued pursuant to the Proposed Private Placement
No. of shares issued under this corporate proposal	15,100,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.2300
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	355,364,340
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 67,371,404.480
Listing Date	27 Mar 2020

icy97

icy97 发表于 3-11-2018 06:27 AM
http://www.bursamalaysia.com/market/listed-companies/company-announcements/5959813

Type	Announcement
Subject	OTHERS
Description	MUTUAL TERMINATION OF THE CONSULTANCY AND PROJECT MANAGEMENT AGREEMENT DATED 30 OCTOBER 2018 BETWEEN LYC LIVING SDN BHD ("LYCL"), A 70% OWNED SUBSIDIARY OF LYC HEALTHCARE BERHAD ("LYC" OR "THE COMPANY") AND LYC WELLNESS SDN BHD (FORMERLY KNOWN AS LYC VENTURE SDN BHD) ("LYCW") (REFERRED AS "AGREEMENT")
The Board of Directors of the Company (“Board”) wishes to announce the mutual termination of the Agreement between LYCL and LYCW.   On 30 October 2018, LYCL had entered into the Agreement with LYCW for the provision of general consultancy, advise and project management by LYCL to LYCW to facilitate the construction, sale and development of LYC Wellness Valley, an integrated health and wellness hub located at Genting Sempah. The Agreement is conditional upon, amongst others, procuring the necessary approvals from the relevant authorities. As at to-date, the necessary approvals from the relevant authorities have yet to be obtained, in particular the development order and the building plans approval for the LYC Wellness Valley, despite various efforts had been made. Pursuant to the above and coupled with the current challenging market condition, LYCL and LYCW had mutually agreed in writing to terminate the Agreement on 9 April 2020. This announcement is dated 9 April 2020.

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

LYC HEALTHCARE BERHAD

Particulars of Substantial Securities Holder

Name	GUNUNG RESOURCES SDN BHD
Address	D-3-3, Block D, Ayer@8, Jalan P8G, Presint 8 Putrajaya 62250 Wilayah Persekutuan Malaysia.
Company No.	71881-T
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name & address of registered holder	Gunung Resources Sdn Bhd D-3-3, Block D, Ayer@8, Jalan P8G, Presint 8, 62250 Putrajaya, Malaysia.

Date interest acquired & no of securities acquired
Date interest acquired	07 Apr 2020
No of securities	2,367,300
Circumstances by reason of which Securities Holder has interest	Acquisition of shares from open market.
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	18,930,800
Direct (%)	5.33
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	10 Apr 2020
Date notice received by Listed Issuer	10 Apr 2020

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR "THE COMPANY")- Incorporation of a New Sub-Subsidiary Company, LYC Medicare (Singapore) Pte. Ltd.
The Board of Directors of LYC wishes to announce that LYC Medicare Sdn. Bhd., a wholly-owned subsidiary of the Company had on 28 April 2020, incorporated a wholly-owned subsidiary known as LYC Medicare (Singapore) Pte. Ltd. ("LYCMS"). The intended principal activity of LYCMS is to engage in the business related to healthcare services. The above incorporation does not have any effect on the share capital of the Company and has no material effect on the earnings and net assets of the Company and its subsidiaries for the financial year ending 31 March 2021. None of the directors and/or substantial shareholders of the Company, or persons connected to such director and/or substantial shareholder has any interest, direct or indirect, in the said incorporation. This announcement is dated 28 April 2020.

icy97

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	LYC HEALTHCARE BERHAD ("LYC OR THE "COMPANY")I.        PROPOSED ACQUISITION BY LYC MEDICARE SDN BHD ("LYC MEDICARE" OR "PURCHASER"), A WHOLLY-OWNED SUBSIDIARY OF LYC, OF A 51% EQUITY INTEREST IN T&T MEDICAL GROUP PTE LTD FOR A PURCHASE CONSIDERATION OF SGD7,293,000; AND II.        PROPOSED PRIVATE PLACEMENT OF UP TO 30% OF THE TOTAL NUMBER OF ISSUED SHARES OF LYC AT AN ISSUE PRICE TO BE DETERMINED AND ANNOUNCED LATER(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
On behalf of the Board of Directors of LYC ("Board"), UOB Kay Hian Securities (M) Sdn Bhd ("UOBKH") wishes to announce that the Company proposes to undertake the following:- i. acquisition by LYC Medicare of a 51% equity interest in T&T Medical Group Pte Ltd ("T&T") at a purchase consideration of SGD7,293,000 (equivalent to RM22,272,822) to be satisfied via a combination of (a) cash amounting to SGD5,304,000 (equivalent to RM16,198,416) and (b) issuance of 1,989,000 redeemable non-cumulative preference shares in LYC Medicare ("RPS") amounting to SGD1,989,000 (equivalent to RM6,074,406), on the terms and conditions contained in the SSA ("Proposed Acquisition"); and ii. private placement of up to 30% of the total number of issued shares of LYC at an issue price to be determined and announced later ("Proposed Private Placement"). The above are collectively referred to as the "Proposals". Further details of the Proposals are set out in the attachment enclosed. This announcement is dated 4 May 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3048095

Attachments LYC - Announcement (Proposals).pdf

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	LYC HEALTHCARE BERHAD ("LYC OR THE "COMPANY")I.        PROPOSED PRIVATE PLACEMENT II.        PROPOSED ACQUISITION OF T&T MEDICAL GROUP PTE LTD  III.        PROPOSED ACQUISITION OF HC ORTHOPAEDIC SURGERY PTE LTD(COLLECTIVELY REFERRED TO AS THE "PROPOSALS")
The terms used herein, unless the context otherwise stated, bear the same meaning as those defined in the earlier announcements in relation to the Proposals. We refer to the earlier announcements dated 4 May 2020, 28 May 2020, 30 June 2020, 3 July 2020, 27 August 2020, 30 October 2020 and 13 November 2020 in relation to the Proposals. On behalf of the Board, UOBKH wishes to announce that all the conditions precedent under the SSA HCOS have been fulfilled, and with the full settlement of the purchase consideration in accordance with the terms of the SSA HCOS, the completion of the Proposed Acquisition of HCOS has taken place on 2 December 2020. This announcement is dated 2 December 2020.

Type	Announcement
Subject	OTHERS
Description	PRESS RELEASE ON THE COMPLETION OF THE ACQUISITIONS OF 51% EQUITY INTEREST IN T&T MEDICAL GROUP PTE LTD AND HC ORTHOPAEDIC SURGERY PTE LTD
Please find attached LYC Healthcare Berhad's press release in relation to the subject matter. Further details of the aforesaid press release are set out in the attachment enclosed. This announcement is dated 2 December 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3110716

Attachments LYC Healthcare Berhad Press Release for HCOS and TT Acquisitions (2 Dec 2020).pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR "THE COMPANY")COVID-19 CONTACT TRACING COLLABORATION AGREEMENT BETWEEN LYC MEDICARE SDN BHD (LYC MEDICARE) AND FORWEN SDN BHD (FORWEN) TO MARKET A COVID-19 CONTACT TRACING APPLICATION IN MALAYSIA ("COLLABORATION AGREEMENT")
The Board of Directors of LYC wishes to announce that LYC Medicare Sdn Bhd [Registration No. 200501003142 (680188-M)], a wholly-owned subsidiary of the Company, had on 14 May 2020 entered into a Covid-19 Contact Tracing Collaboration Agreement with Forwen Sdn Bhd [Registration No. 200501024842 (706975-U)] to market an application called the “Forwen Tracker” to centralise Big Data system with a simple and fast combination of web application as well as Android and iOS application for data collection in relation to the Covid-19 outbreak. Kindly refer to the attached announcement on the Collaboration Agreement. This announcement is dated 14 May 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3050191

Attachments Announcement - Covid-19 Contact Tracing Collaboration Agreement (14.5.2020).pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR "THE COMPANY") HYGIENE AND DISINFECTION SERVICES COLLABORATION AGREEMENT BETWEEN LYC MEDICARE SDN BHD ("LYC MEDICARE") AND BIOFRESH HYGIENE SERVICES SDN BHD ("BIOFRESH") TO MARKET CLEANLINESS, HYGIENE AND SANITATION SERVICES IN MALAYSIA ("COLLABORATION AGREEMENT")
The Board of Directors of LYC wishes to announce that LYC Medicare Sdn Bhd [Registration No. 200501003142 (680188-M)], a wholly-owned subsidiary of the Company, had on 18 May 2020 entered into a Hygiene and Disinfection Services Collaboration Agreement with Biofresh Hygiene Services Sdn Bhd [Registration No. 200601028192 (747948-D)] to market a range of cleanliness, hygiene and sanitation services including manual and automatic hand sanitizer dispensers, hand soap dispenser, toilet seat sanitizer, lady bin as well as disinfection service, on behalf of Biofresh. Kindly refer to the attached announcement on the Collaboration Agreement. This announcement is dated 18 May 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3051005

Attachments Announcement - Hygiene and Disinfection Services Collaboration Agreement (18.5.2020).pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR THE "COMPANY") - INCORPORATION OF A 51% OWNED SUBSIDIARY
1. Introduction The Board of Directors of LYC wishes to announce that the Company has on 19 May 2020 incorporated a Fifty-One percent (51%) owned subsidiary known as KLIMC Sdn Bhd [Registration No. 202001011665 (1367985-V)]("KLIMC"). The remaining Forty-Nine percent (49%) shareholding is held by Urban Masterpiece Sdn Bhd [Registration No. 201601027097 (1198036-A)](“Urban Masterpiece”). 2. Information of KLIMC KLIMC was incorporated on 19 May 2020 as a private limited company by shares in Malaysia under the Companies Act 2016. The share capital of KLIMC as at the date of announcement is Ringgit Malaysia One Hundred (RM100.00) only comprising One Hundred (100) ordinary shares. LYC holds Fifty-One (51) shares for Ringgit Malaysia Fifty-One (RM51.00) only, representing Fifty-One percent (51%) shareholding of KLIMC while Urban Masterpiece holds Forty-Nine (49) shares for Ringgit Malaysia Forty-Nine (RM49.00) only, representing Forty-Nine percent (49%) shareholding of KLIMC. The intended principal activities of KLIMC are to own and to carry on the business of running hospitals. The current directors of KLIMC are Mr Sui Diong Hoe and Dr. Nor Azeera Binti Wahab. 3. Information of Urban Masterpiece Urban Masterpiece is a Malaysian company with business interest in water treatment technology, flood mitigation infrastructures, security and defense solutions. The share capital of Urban Masterpiece is One Million Ringgit (RM1,000,000) only comprising One Million (1,000,000) ordinary shares. The shareholders and directors of Urban Masterpiece are Encik Mohamad Shohor bin Mahamud and Datuk Wan Abd Halim bin Abd Majid who holds five hundred thousand (500,000) shares each respectively. The founders, shareholders, directors and advisors of the company are having more than 25 years of working experience ranging from architectural design, real estate development, construction, aerostructure composite manufacturing and aerospace engineering services. 4. Rationale The Company is working with Urban Masterpiece to explore the possibility of set up, own and operate a hospital with a focus on attracting medical tourism with a focus on fertility, cosmetic and aesthetic, orthopaedic and osteperosis at a location to be identified at a later date and is subject to approval of necessary authorities. According to the Malaysia Healthcare Travel Council, the healthcare travel industry in Malaysia grew by 14% in 2019 with recorded RM1.5 billion in receipts from 1.2 million medical tourists. The Company intends to leverage on the healthcare expertise of LYC Healthcare group of companies and the construction expertise of Urban Masterpiece to ensure the successful execution of the proposed project. 5. Financial Effect of the Incorporation of KLIMC The incorporation of KLIMC does not have any effect on the share capital and substantial shareholders’ shareholdings of LYC. It is also not expected to have any material effect on the net assets, gearing and earnings of LYC for the financial year ending 31 March 2021. 6. Directors’ and Major Shareholders’ Interests None of the directors and/or major shareholders of the Company, or persons connected to such directors and/or major shareholders, has any interest, direct or indirect, in the said incorporation. This announcement is dated 19 May 2020.

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	LYC HEALTHCARE BERHAD ("LYC OR THE "COMPANY")PROPOSED ACQUISITION BY LYC MEDICARE SDN BHD ("LYC MEDICARE" OR "PURCHASER"), A WHOLLY-OWNED SUBSIDIARY OF LYC, OF A 51% EQUITY INTEREST IN HC ORTHOPAEDIC SURGERY PTE LTD FOR A PURCHASE CONSIDERATION OF SGD6,936,000
On behalf of the Board of Directors of LYC ("Board"), UOB Kay Hian Securities (M) Sdn Bhd ("UOBKH") wishes to announced that LYC Medicare, a wholly-owned subsidiary of LYC, had on 28 May 2020 entered into a conditional share sale agreement ("SSA") with Chan Ying Ho and Beyond Wellness Group Pte Ltd ("BWG") ("Vendors") for the proposed acquisition by LYC Medicare of a 51% equity interest in HC Orthopaedic Surgery Pte Ltd ("HCOS") for a purchase consideration of SGD6,936,000 (equivalent to RM21,293,520) to be satisfied entirely in cash, on the terms and conditions contained in the SSA ("Proposed Acquisition"). Further details of the Proposed Acquisition are set out in the attachment enclosed. This announcement is dated 28 May 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3053569

Attachments LYC - Announcement (Proposed Acquisition of HCOS).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,098	2,470	12,434	7,603
2	Profit/(loss) before tax	-4,309	-2,238	-10,161	-7,525
3	Profit/(loss) for the period	-4,424	-2,300	-10,269	-5,897
4	Profit/(loss) attributable to ordinary equity holders of the parent	-4,050	-2,253	-9,643	-5,881
5	Basic earnings/(loss) per share (Subunit)	-1.19	-0.69	-2.91	-1.97
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0600		0.0700

icy97

LYC HEALTHCARE BERHAD

Date of change	04 Aug 2020
Name	DATO' LIM CHENG POH
Age	71
Gender	Male
Nationality	Malaysia
Designation	Chairman
Directorate	Independent and Non Executive
Type of change	Resignation
Reason	To pursue his own personal interests.
Details of any disagreement that he/she has with the Board of Directors	No
Whether there are any matters that need to be brought to the attention of shareholders	No

Qualifications

No

Qualifications

Major/Field of Study

Institute/University

Additional Information

Working experience and occupation	N/A
Family relationship with any director and/or major shareholder of the listed issuer	None
Any conflict of interests that he/she has with the listed issuer	None
Details of any interest in the securities of the listed issuer or its subsidiaries	Indirect interest of 1,600,000 ordinary shares.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,628	2,686	2,628	2,686
2	Profit/(loss) before tax	-2,708	-1,592	-2,708	-1,592
3	Profit/(loss) for the period	-2,706	-1,590	-2,706	-1,590
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,576	-1,543	-2,576	-1,543
5	Basic earnings/(loss) per share (Subunit)	-0.72	-0.47	-0.72	-0.47
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0500		0.0700

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	LYC HEALTHCARE BERHAD ("LYC OR THE "COMPANY")I.        SUBSCRIPTION BY LYC MEDICARE SDN BHD (A WHOLLY-OWNED SUBSIDIARY OF LYC) OF 30% EQUITY INTEREST IN SEL STEM SDN BHD ("SEL STEM"); ANDII.        SHAREHOLDERS' AGREEMENT BETWEEN LYC MEDICARE SDN BHD, ALL LIFE ADVANCE IMMUNOLOGY SDN BHD, LIEF CAPITAL SDN BHD AND KHOO TOH HOCK
The Board of Directors of LYC ("Board"), wishes to announce that LYC Medicare Sdn Bhd ("LYC Medicare"), a wholly-owned subsidiary of LYC, had on 1 October 2020 subscribed for 300,000 new ordinary shares in Sel Stem, representing 30% equity interest in Sel Stem, for a cash consideration of RM300,000 ("Subscription"). In conjunction thereto, LYC Medicare, had on even date entered into a shareholders' agreement with All Life Advance Immunology Sdn Bhd ("ALAI"), Lief Capital Sdn Bhd ("LIEF") and Khoo Toh Hock ("KTH") to regulate their rights and obligations as shareholders of Sel Stem and in respect of the management and business affairs of Sel Stem ("SHA"). The business of Sel Stem shall be the making of a proposed investment in the ordinary shares of Advanced Neuroscience & Orthopaedic Clinic Sdn Bhd ("ANOC"), which is principally involved in the provision of consultancy services in medical and healthcare related fields including the sale of pharmaceutical products. Please refer to the attachment for further details. This announcement is dated 1 October 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092827

Attachments LYC - Announcement (FINAL).pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LYC HEALTHCARE BERHAD ("LYC" OR THE "COMPANY") - PROPOSED ISSUANCE OF UP TO 45,000,000 NEW REDEEMABLE PREFERENCE SHARES ("RPS") BY LYC MEDICARE SDN BHD, A WHOLLY OWNED SUBSIDIARY OF LYC, TO KENANGA INVESTORS BERHAD AT AN ISSUE PRICE OF RM1.00 PER RPS ("PROPOSED ISSUANCE OF RPS")
The Board of Directors of LYC wishes to announce that LYC Medicare Sdn Bhd [Registration No. 200501003142 (680188-M)] ("LYC Medicare"), a wholly-owned subsidiary of LYC, proposes to undertake the Proposed Issuance of RPS. On even date, the Company entered into a conditional subscription agreement with Kenanga Investors Berhad [Registration No.: 199501024358 (353563-P)] and LYC Medicare in relation to the Proposed Issuance of RPS. Kindly refer to the attached announcement on the Proposed Issuance of RPS. This announcement is dated 15 October 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3096699

Attachments Proposed Issuance of RPS (15.10.2020).pdf